SCHEMBL24224443

SCHEMBL24224443

CCc1ccc2c(n1)N(C)C(=O)CO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 2/20 0.38
▸ PDE3B Q13370 2/20 0.37
▸ PDE3A Q14432 2/20 0.37
▸ GABRG2 P18507 6/20 0.36
▸ GABRB3 P28472 6/20 0.36
▸ GABRA5 P31644 6/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ REN P00797 1/20 0.33
▸ HTT P42858 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19200134 0.81 PIK3CD (0.32) KCNH2PARP1RENHTTHTR1A
SCHEMBL17813516 0.80 HTR1D (0.41) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL29844807 0.78 PDE3B (0.41) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL23214142 0.78 PDE3B (0.41) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL13924120 0.78 PDE3B (0.39) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL12235341 0.77 HTT (0.35) RENHTTTSHRBRD4
SCHEMBL15979065 0.76 KCNH2 (0.43) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL23240416 0.76 PDE3B (0.37) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL14476154 0.76 FGFR4 (0.40) KCNH2PDE3BPDE3AGABRG2GABRB3
SCHEMBL764050 0.71 PARP1 (0.50) KCNH2PDE3BPDE3AGABRA5PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024901-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024901-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR KCNH2 2471/4885PDE3B 125/4885PDE3A 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback